Earnings Per Share (TTM) A company's net income for the trailing ... Source: FactSet Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m ...

It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc ...

Gilead Sciences is just a few weeks away from an ... at the time it believed that the drug has a “best-in-disease” profile for PBC, which affects around 1 in 1,000 women over the age of ...

Over 230 patients enrolled in potential registration-enabling trial in 1L HLA-A2-negative MUM, and median PFS readout targeted by year-end 2025 95 patients enrolled ...

On Saturday April 5, UC Riverside will host its second annual gala at the Student Recreation Center. The evening will ...

Gilead Sciences Inc. closed 1.35% below its 52-week high of $106.69, which the company achieved on February 14th.

Fintel reports that on February 18, 2025, Deutsche Bank upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Hold ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings per share (EPS) estimates for Gilead Sciences in a report ...

Needham & Company LLC restated their hold rating on shares of Gilead Sciences (NASDAQ:GILD – Free Report) in a research report sent to investors on Wednesday,Benzinga reports. Other analysts also ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue ...